Statera Biopharma is a biopharmaceutical company. Co.'s product candidate, Entolimod is a Toll-like receptor 5 (TLR5) agonist, which Co. is developing as a medical radiation countermeasure for reducing the risk of death following exposure to potentially lethal irradiation Acute Radiation Syndrome. Co.'s other product candidate, Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, a secretory non-glycosylated version of entolimod Co. is also developing through its subsidiary, Panacela Labs, Inc. Two randomized, placebo-controlled, dose-ranging studies of Mobilan in men with prostate cancer are ongoing in the Russian Federation. The STAB stock yearly return is shown above.
The yearly return on the STAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2013 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the STAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|